Clinical Responses in KRAS-Mutant Solid Cancers
An investigational KRAS inhibitor induced clinical responses in patients with non-small cell lung cancer (NSCLC) and colorectal cancer harboring KRAS mutations, according to the results of a new study. Data demonstrating the efficacy of KRAS inhibitor MRTX849 in preclinical studies and in two patients with solid tumors were published simultaneously in Cancer Discovery (2019; doi:…
